Why is REGENXBIO facing a securities class action lawsuit?

Investors allege REGENXBIO made misleading statements or failed to disclose material information about the efficacy and safety of its RGX-111 clinical trial, impacting the company’s stock price when concerns emerged.

What is RGX-111 and why is it central to the REGENXBIO lawsuit?

RGX-111 is a gene therapy candidate under development by REGENXBIO. The lawsuit focuses on whether the company accurately disclosed trial data regarding its effectiveness and safety profile.

What are investors alleging about REGENXBIO’s clinical trial disclosures?

The complaint claims REGENXBIO overstated or omitted key facts about RGX-111’s trial results, creating a misleading impression of the drug’s prospects and regulatory pathway.

Who may qualify to participate in the REGENXBIO class action?

Investors who purchased or acquired REGENXBIO securities between February 9, 2022 and January 27, 2026 and suffered losses may be eligible to participate in the securities class action.

What is the deadline to seek lead plaintiff status in the REGENXBIO lawsuit?

Investors seeking to serve as lead plaintiff in the federal securities class action against REGENXBIO must file a motion by April 14, 2026 to preserve their right to represent the class.

REGENXBIO Inc. - Faruqi & Faruqi LLP

REGENXBIO Inc.

Join Action

Case Details

Ticker RGNX

Class Period 02/09/2022 - 01/27/2026

Lead Plaintiff Deadline 04/14/2026

Days Left to Seek Plaintiff

If you are a REGENXBIO investor who suffered a loss and would like to learn more, you can provide your information below:

If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) and reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning the efficacy and safety of its RGX-111 trial study.

Lead Plaintiff Deadline: April 14, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

REGENXBIO Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify